BioE Executives to Present at 35th Annual International Society for Experimental Hematology Meeting.Company to participate in IP and marketing symposium and present scientific data further demonstrating the MLPC's potential as a new, powerful tool for regenerative medicine and drug screening ST. PAUL St. Paul as a missionary he fearlessly confronts the “perils of waters, of robbers, in the city, in the wilderness.” [N.T.: II Cor. 11:26] See : Bravery , Minn. -- BioE([R]), Inc., a biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company providing human umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young as enabling, high-quality cellular tools for drug discovery and therapeutic research, announced today its executives will participate in and present at the 35th Annual International Society for Experimental Hematology The International Society for Experimental Hematology (ISEH) is a learned society which deals with hematology, the study of the blood system and its diseases, including those caused by exposure to nuclear radiation. (ISEH ISEH International Society for Ecosystem Health ) meeting later this week at the Hyatt Regency in downtown Minneapolis. BioE also announced it has launched a new, enhanced corporate Web site at www.bioe.com. ISEH 2006 Annual Meeting: IP and Marketing Symposium Michael Haider, president and chief executive officer for BioE, will participate in a symposium titled "Intellectual Property and Marketing Issues Related to Cells and Cell-Based Therapeutics" to be held Thurs., Sept. 28, 2006. Haider and other panel participants will focus their discussion on stem cells, including patent claim strategies, recent developments in cell-related patent law and challenges associated with marketing a cell or cell-based therapeutic. Specifically, Haider will discuss BioE's experiences patenting and marketing its rare cord blood cord blood n. Blood present in the umbilical vessels at the time of delivery. stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. , the Multi-Lineage Progenitor Cell([TM]) (MLPC MLPC Marxist-Leninist Party of Canada MLPC Midwest Lakes Policy Center (Madison, Wisconsin) MLPC Movement for the Liberation of the Central African People (Central African Republic) ([TM])), which the company announced the discovery of in 2004 and subsequently commercialized in July 2005. ISEH 2006 Annual Meeting: Scientific Poster Presentations The MLPC also will be the subject of two poster presentations by Daniel Collins, Ph.D., executive vice president and chief scientific officer for BioE, at the ISEH 2006 annual meeting. In these presentations, Dr. Collins will share scientific data comparing the MLPC to bone marrow- and cord blood-derived mesenchymal stem cells (MSCs), as well as research on the MLPC's flexibility to differentiate into numerous cell types in various two- and three-dimensional cell culture conditions, including on matrices and scaffolds. This scientific data further demonstrates the MLPC's potential as a new, powerful tool for regenerative medicine research, as well as tissue engineering, drug discovery/toxicology screening and the development of more effective extracellular matrix extracellular matrix (eksˈ·tr  ·selˑ·y scaffolds. "As we and our research collaborators around the world continue to work with the MLPC, it's becoming clear our stem cell is leading a new category of highly functional stem cells from cord blood," Dr. Collins said. "We still have much to learn, but it is within reason that the MLPC could directly impact regenerative medicine and drug development processes in the very near-term." BioE Launches New Web Site BioE also announced today it has re-launched its corporate Web site Co www.bioe.com. The new site will enable the company to better communicate with its many audiences, including the scientific community about its MLPC and the cord blood banking industry about its soon-to-be-released cord blood processing system, PrepaCyte([R])-CB. A variety of news and events and technical and non-technical information about BioE and its products can be found on the site. The site also provides the ability for academic institutions, biotechnology organizations and pharmaceutical companies around the world to purchase the MLPC. About BioE Headquartered in St. Paul, Minn., BioE is a biomedical company providing human cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of as enabling, high-quality cellular tools for drug discovery and therapeutic research. The company's novel Multi-Lineage Progenitor Cell([TM]) (MLPC([TM])) Co derived from human umbilical cord blood and obtained using PrepaCyte([R]), the company's proprietary cell isolation platform Co provides clinicians and researchers a flexible, long-term and non-controversial tool for therapeutic research and drug discovery and screening. BioE is privately owned and was founded in 1993. For more information about the company, please visit www.bioe.com or call (800) 350-6466. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion